BIRC5 and breast cancer: These findings are consistent with a recent in silico analysis by Dai et al. and with the observation by Hamy et al. that BIRC5 predicts a worse RFS in stage II/III BC patients of all intrinsic subtypes who do not achieve a pCR after neoadjuvant chemotherapy [40,41].